FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912695313> ?p ?o ?g. }

• W2912695313 endingPage "41" @default.
• W2912695313 startingPage "32" @default.
• W2912695313 abstract "Background Neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) does not achieve effective control of distant metastases. Induction chemotherapy is a promising strategy, and bevacizumab (BV) could improve the results of CRT. 5-Fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) plus BV is a treatment option in metastatic colorectal cancer. We evaluate feasibility and efficacy of neoadjuvant treatment comprising induction FOLFOXIRI plus BV followed by CRT with fluoropyrimidines plus BV. Methods In this phase II single-arm trial, patients node-positive or clinical T4 or high-risk T3 LARC underwent 6 cycles of induction FOLFOXIRI plus BV, followed by CRT (50.4 Gy plus concomitant capecitabine) and BV (5 mg/kg on days 1, 15 and 28). Surgery was planned 8 weeks after completion of CRT. Primary end-point was 2-year disease-free survival (DFS). Results We enrolled 49 patients: All but one (withdrewing consent after enrolment) were included in the per-protocol analyses. The study met its primary end-point: 36 patients were free of recurrence at 2 years (2-y DFS: 80.45%, 95% confidence interval [CI]: 78.79–82.10). Forty-four patients underwent surgery; pathologic complete response rate was 36.4%. Forty-six patients completed induction: neutropenia (41.6%) and diarrhoea (12.5%) were main G3/4 toxicities. Forty-five patients received CRT, but the protocol was amended and the capecitabine schedule during CRT was slightly modified after 13 patients due to the incidence of G3 hand-foot syndrome and proctitis (23.1%). After amendment, no severe events during CRT were reported. Conclusions FOLFOXIRI plus BV followed by CRT plus BV is feasible and active. Results in terms of DFS suggest that this strategy may improve distant disease control in LARC." @default.
• W2912695313 created "2019-02-21" @default.
• W2912695313 creator A5000699628 @default.
• W2912695313 creator A5003285966 @default.
• W2912695313 creator A5006681229 @default.
• W2912695313 creator A5017474339 @default.
• W2912695313 creator A5028325185 @default.
• W2912695313 creator A5029495871 @default.
• W2912695313 creator A5034356923 @default.
• W2912695313 creator A5034659601 @default.
• W2912695313 creator A5036582340 @default.
• W2912695313 creator A5036615333 @default.
• W2912695313 creator A5037889066 @default.
• W2912695313 creator A5047673996 @default.
• W2912695313 creator A5051613962 @default.
• W2912695313 creator A5058514609 @default.
• W2912695313 creator A5059511899 @default.
• W2912695313 creator A5061278061 @default.
• W2912695313 creator A5071279666 @default.
• W2912695313 creator A5074096990 @default.
• W2912695313 creator A5081985776 @default.
• W2912695313 creator A5082573156 @default.
• W2912695313 creator A5084106899 @default.
• W2912695313 creator A5085239925 @default.
• W2912695313 date "2019-03-01" @default.
• W2912695313 modified "2023-10-18" @default.
• W2912695313 title "Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial" @default.
• W2912695313 cites W1899767765 @default.
• W2912695313 cites W1977168996 @default.
• W2912695313 cites W1993780950 @default.
• W2912695313 cites W2020014009 @default.
• W2912695313 cites W2029562445 @default.
• W2912695313 cites W2037108267 @default.
• W2912695313 cites W2047778994 @default.
• W2912695313 cites W2049743143 @default.
• W2912695313 cites W2091770001 @default.
• W2912695313 cites W2097656606 @default.
• W2912695313 cites W2099764000 @default.
• W2912695313 cites W2102220427 @default.
• W2912695313 cites W2106845199 @default.
• W2912695313 cites W2107710830 @default.
• W2912695313 cites W2108051921 @default.
• W2912695313 cites W2109134893 @default.
• W2912695313 cites W2113029107 @default.
• W2912695313 cites W2115153468 @default.
• W2912695313 cites W2124695217 @default.
• W2912695313 cites W2130596822 @default.
• W2912695313 cites W2134519717 @default.
• W2912695313 cites W2155492044 @default.
• W2912695313 cites W2288210984 @default.
• W2912695313 cites W2305876893 @default.
• W2912695313 cites W2337299291 @default.
• W2912695313 cites W2461479776 @default.
• W2912695313 cites W2584708289 @default.
• W2912695313 cites W2594373254 @default.
• W2912695313 cites W2602429131 @default.
• W2912695313 cites W2608705358 @default.
• W2912695313 cites W2624056733 @default.
• W2912695313 cites W2793619720 @default.
• W2912695313 cites W2807156047 @default.
• W2912695313 cites W2894033792 @default.
• W2912695313 cites W2895933119 @default.
• W2912695313 doi "https://doi.org/10.1016/j.ejca.2019.01.006" @default.
• W2912695313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30739838" @default.
• W2912695313 hasPublicationYear "2019" @default.
• W2912695313 type Work @default.
• W2912695313 sameAs 2912695313 @default.
• W2912695313 citedByCount "23" @default.
• W2912695313 countsByYear W29126953132020 @default.
• W2912695313 countsByYear W29126953132021 @default.
• W2912695313 countsByYear W29126953132022 @default.
• W2912695313 countsByYear W29126953132023 @default.
• W2912695313 crossrefType "journal-article" @default.
• W2912695313 hasAuthorship W2912695313A5000699628 @default.
• W2912695313 hasAuthorship W2912695313A5003285966 @default.
• W2912695313 hasAuthorship W2912695313A5006681229 @default.
• W2912695313 hasAuthorship W2912695313A5017474339 @default.
• W2912695313 hasAuthorship W2912695313A5028325185 @default.
• W2912695313 hasAuthorship W2912695313A5029495871 @default.
• W2912695313 hasAuthorship W2912695313A5034356923 @default.
• W2912695313 hasAuthorship W2912695313A5034659601 @default.
• W2912695313 hasAuthorship W2912695313A5036582340 @default.
• W2912695313 hasAuthorship W2912695313A5036615333 @default.
• W2912695313 hasAuthorship W2912695313A5037889066 @default.
• W2912695313 hasAuthorship W2912695313A5047673996 @default.
• W2912695313 hasAuthorship W2912695313A5051613962 @default.
• W2912695313 hasAuthorship W2912695313A5058514609 @default.
• W2912695313 hasAuthorship W2912695313A5059511899 @default.
• W2912695313 hasAuthorship W2912695313A5061278061 @default.
• W2912695313 hasAuthorship W2912695313A5071279666 @default.
• W2912695313 hasAuthorship W2912695313A5074096990 @default.
• W2912695313 hasAuthorship W2912695313A5081985776 @default.
• W2912695313 hasAuthorship W2912695313A5082573156 @default.
• W2912695313 hasAuthorship W2912695313A5084106899 @default.
• W2912695313 hasAuthorship W2912695313A5085239925 @default.
• W2912695313 hasConcept C121608353 @default.
• W2912695313 hasConcept C126322002 @default.
• W2912695313 hasConcept C141071460 @default.

• next